全文获取类型
收费全文 | 134753篇 |
免费 | 8612篇 |
国内免费 | 708篇 |
专业分类
耳鼻咽喉 | 1284篇 |
儿科学 | 4523篇 |
妇产科学 | 3325篇 |
基础医学 | 18907篇 |
口腔科学 | 4355篇 |
临床医学 | 14786篇 |
内科学 | 28898篇 |
皮肤病学 | 3099篇 |
神经病学 | 13115篇 |
特种医学 | 3026篇 |
外国民族医学 | 1篇 |
外科学 | 11880篇 |
综合类 | 782篇 |
一般理论 | 111篇 |
预防医学 | 14538篇 |
眼科学 | 2060篇 |
药学 | 9074篇 |
中国医学 | 441篇 |
肿瘤学 | 9868篇 |
出版年
2023年 | 1102篇 |
2022年 | 2015篇 |
2021年 | 4133篇 |
2020年 | 2700篇 |
2019年 | 3788篇 |
2018年 | 4232篇 |
2017年 | 3210篇 |
2016年 | 3767篇 |
2015年 | 4153篇 |
2014年 | 5421篇 |
2013年 | 7315篇 |
2012年 | 10920篇 |
2011年 | 11303篇 |
2010年 | 6192篇 |
2009年 | 5271篇 |
2008年 | 9280篇 |
2007年 | 9422篇 |
2006年 | 8805篇 |
2005年 | 8261篇 |
2004年 | 7492篇 |
2003年 | 6802篇 |
2002年 | 6193篇 |
2001年 | 816篇 |
2000年 | 595篇 |
1999年 | 833篇 |
1998年 | 1193篇 |
1997年 | 926篇 |
1996年 | 825篇 |
1995年 | 708篇 |
1994年 | 654篇 |
1993年 | 572篇 |
1992年 | 433篇 |
1991年 | 312篇 |
1990年 | 317篇 |
1989年 | 299篇 |
1988年 | 275篇 |
1987年 | 230篇 |
1986年 | 267篇 |
1985年 | 239篇 |
1984年 | 248篇 |
1983年 | 241篇 |
1982年 | 295篇 |
1981年 | 253篇 |
1980年 | 263篇 |
1979年 | 132篇 |
1978年 | 135篇 |
1977年 | 130篇 |
1976年 | 121篇 |
1975年 | 102篇 |
1974年 | 101篇 |
排序方式: 共有10000条查询结果,搜索用时 797 毫秒
81.
Marie Warrer Petersen Tine Sylvest Meyhoff Marie Helleberg Maj-Brit Nørregaard Kjær Anders Granholm Carl Johan Steensen Hjortsø Thomas Steen Jensen Morten Hylander Møller Peter Buhl Hjortrup Mik Wetterslev Gitte Kingo Vesterlund Lene Russell Vibeke Lind Jørgensen Klaus Tjelle Thomas Benfield Charlotte Suppli Ulrik Anne Sofie Andreasen Thomas Mohr Morten H. Bestle Lone Musaeus Poulsen Mette Friberg Hitz Thomas Hildebrandt Lene Surland Knudsen Anders Møller Christoffer Grant Sølling Anne Craveiro Brøchner Bodil Steen Rasmussen Henrik Nielsen Steffen Christensen Thomas Strøm Maria Cronhjort Rebecka Rubenson Wahlin Stephan Jakob Luca Cioccari Balasubramanian Venkatesh Naomi Hammond Vivekanand Jha Sheila Nainan Myatra Christian Gluud Theis Lange Anders Perner 《Acta anaesthesiologica Scandinavica》2020,64(9):1365-1375
Introduction
Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure. Corticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations. However, corticosteroids have undesirable effects, including longer time to viral clearance. Clinical equipoise on the use of corticosteroids for COVID-19 exists.Methods
The COVID STEROID trial is an international, randomised, stratified, blinded clinical trial. We will allocate 1000 adult patients with COVID-19 receiving ≥10 L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo (0.9% saline) for 7 days. The primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1 year; and health-related quality of life at 1 year. We will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28 days. The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals.Discussion
The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.82.
Darren R. Feldman MD Yasser Ged MBBS Chung-Han Lee PhD Andrea Knezevic MS Ana M. Molina MD Ying-Bei Chen PhD Joshua Chaim DO Devyn T. Coskey MS Samuel Murray MS Satish K. Tickoo MD Victor E. Reuter MD Sujata Patil PhD Han Xiao MD Jahan Aghalar MD Arlyn J. Apollo MD Maria I. Carlo MD Robert J. Motzer MD Martin H. Voss MD 《Cancer》2020,126(24):5247-5255
83.
84.
Timothee Dub Bolette Sborg Peter Henrik Andersen Thorolfur Gudnason Hanne Nkleby Ann Lindstrand Rose-Marie Carlsson Hanna Nohynek 《Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin》2021,26(4)
Healthcare workers (HCWs) are at increased risk of both exposure and transmission of infectious disease. Two European Union (EU) directives state that health services are responsible for assessing their employees’ potential exposure to infectious diseases and offering immunisation free of charge. We assessed current policy for immunisation of HCWs and the availability of vaccine coverage data in the Nordic countries by surveying national vaccination experts in Denmark, Finland, Iceland, Norway and Sweden, as well as Swedish county medical officers (CMOs). All national experts and 17 of 21 Swedish CMOs responded. All EU countries had transposed the European directives into national law, while Norway and Iceland had similar national legislation. Recommendations or guidelines were issued in Denmark, Finland, Iceland, Norway and 15 of 17 responding Swedish counties. The range of diseases covered differed by countries and Swedish counties. HCW vaccine coverage data were not systematically collected; incomplete estimates were only available for Finland and two Swedish counties. In conclusion, recommendations or guidelines exist in the Nordic countries, but their impact cannot be assessed, as vaccine uptake among HCWs is not currently measured. Systematic collection of data is a necessary step towards improving HCW immunisation policy and practice in the Nordic countries. 相似文献
85.
86.
87.
Martin J. Kurian Peter J. Rentzepis Ann M. Carracher Kelly L. Close 《Journal of Diabetes》2019,11(9):700-702
Martin J. Kurian, Peter J. Rentzepis, Ann M. Carracher, and Kelly L. Close are of Close Concerns ( http://www.closeconcerns.com ), a healthcare information company focused exclusively on diabetes and obesity care. Close Concerns publishes Closer Look, a periodical that brings together news and insights in these areas. Each month, the Journal of Diabetes includes this News feature, in which Kurian, Rentzepis, Carracher, and Close review the latest developments relevant to researchers and clinicians. 相似文献
88.
Paolo Mazzone Fabrizio Stocchi Salvatore Galati Angelo Insola Maria Grazia Altibrandi Nicola Modugno Domenicantonio Tropepi Livia Brusa Alessandro Stefani 《Neuromodulation》2006,9(3):221-228
Objectives. Traditional deep brain stimulation (DBS) at the subthalamic nucleus (STN) has proved to be efficacious on core Parkinsonian symptoms. However, very disabling l ‐dopa–induced abnormal involuntary movements (AIMs) and axial signs are slightly affected, suggesting that we target less conventional targets. Our candidates for DBS were the globus pallidus internus (GPi) plus the intralaminar thalamic complex (Pf or CM), given its extensive functional links with basal ganglia nuclei. Materials and Methods. The routine utilization of our innovative stereotactic apparatus allows us to implant, at the same time, both the CM‐Pf complex together with the GPi in six Parkinson disease patients. Both intraoperative and postoperative neurophysiologic assessments helped us recognize functional subregions while optimizing implantation of electrodes. Unified Parkinson disease rating scale (UPDRS) motor scores, AIMs, and freezing were carefully blindly evaluated for each condition. Results. A significant amelioration of UPDRS scores was achieved by simultaneous activation of both targets. CM‐Pf activation was only slightly effective in reducing rigidity and akinesia, but more efficacious on freezing. Not surprisingly, AIMs were peculiarly decreased by the activation of the permanent electro‐catheter in the posteroventral GPi. Conclusions. These findings confirm that, in selected patients, it is conceivable to target structures other than the conventional STN in order to maximize clinical benefit. 相似文献
89.
Joseph Biederman Haitao Gao Ann K Rogers Thomas J Spencer 《Neuropsychopharmacology》2006,60(10):1106-1110
BACKGROUND: The validity of parent reports regarding children's attention-deficit/hyperactivity disorder (ADHD) symptoms has been questioned. This study assessed whether parent reports were as sensitive as teacher reports to document change in ADHD symptoms during clinical trials with atomoxetine. METHODS: Data were compared from two randomized, double-blind, placebo-controlled clinical trials of atomoxetine using different versions (parent or teacher) of the same rating scale (Attention-Deficit/Hyperactivity Disorder Rating Scale-IV [parent or teacher] Version: Investigator Administered and Scored - ADHD RS). Exclusion criteria included history of bipolar disorder, psychosis, seizures, alcohol abuse, or positive drug screen. Patients (6-16 years old) were treated with atomoxetine (titrated to a maximum dose of 1.8 mg/kg/day) administered once daily for up to 7 weeks. Parent and teacher ratings were compared using an analysis of covariance (ANCOVA) model. RESULTS: The analysis (n = 318) showed that treatment effects (mean change, baseline to endpoint) were similar between parent and teacher ratings (total, p = .762; inattention, p = .519; hyperactive/impulsive, p = .955). Effect sizes also were similar based on total scores (parent ratings = .69; teacher ratings = .63). CONCLUSIONS: Parent reports are as sensitive as teacher reports in assessing the efficacy of long-acting pharmacologic treatment for ADHD in children during clinical trials using the nonstimulant atomoxetine. 相似文献
90.